Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells

Experimental Neurology

Volumn 250, Issue , 2013, Pages 384-396

  Garrido Gil, Pablo ^a,b   Rodriguez Pallares, Jannette ^a,b   Dominguez Meijide, Antonio ^a,b   Guerra, Maria J ^a,b   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Ageing; Dopamine; Microglia; NADPH oxidase; Neuroinflammation; NF kB; Oxidative stress; Parkinson's disease; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; FERRITIN; FERROPORTIN; I KAPPA B; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; OXIDOREDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; ENZYME ACTIVATION; GLIA CELL; IRON BALANCE; IRON TRANSPORT; MESENCEPHALON; MICROGLIA; NERVE CELL CULTURE; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TISSUE CULTURE;

2′,3′-CYCLIC NUCLEOTIDE 3′-PHOSPHODIESTERASE; AGEING; AII; AMMONIUM PYRROLIDINEDITHIOCARBAMATE; ANGIOTENSIN II; ARA-C; CNPASE; CYTOSINE-Β-D-ARABINO-FURANOSIDE; DAYS IN VITRO; DIV; DIVALENT METAL TRANSPORTER 1; DMT1; DOPAMINE; FERROPORTIN 1; FP1; IL-1 Β; INTERLEUCIN 1 Β; MICROGLIA; N-ACETYL-CYSTEINE; NAC; NADPH-OXIDASE; NEUROINFLAMMATION; NF-KB; OXIDATIVE STRESS; PARKINSON'S DISEASE; PD; PDTC; PG-SK; PHEN GREEN-SK; RAS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; ROS; SN; SN COMPACTA; SNC; SUBSTANTIA NIGRA; TF; TFR; TH; TRANSFERRIN; TRANSFERRIN RECEPTOR; TYROSINE HYDROXYLASE; WB; WESTERN BLOT;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; DOPAMINERGIC NEURONS; FLUORESCENT ANTIBODY TECHNIQUE; HOMEOSTASIS; IRON; MALE; MICROGLIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN;

EID: 84887543491     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.10.013     Document Type: Article

References (55)

1. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
2. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res. 2005, 96:818-822.
3. Cheepsunthorn P., Radov L., Menzies S., Reid J., Connor J.R. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 2001, 35:53-62.
4. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Collier T.J., Carvey P.M. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 2007, 26:56-65.
5. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 1995, 65:717-724.
6. Connor J.R., Boyer P.J., Menzies S.L., Dellinger B., Allen R.P., Ondo W.G., Earley C.J. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309.
7. Crawford G.D., Le W.D., Smith R.G., Lie W.J., Stefani E., Appel S.H. A novel N18TG2×mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 1992, 12:3392-3398.
8. Double K.L., Halliday G.M. New face of neuromelanin. J. Neural Transm. Suppl. 2006, 70:119-123.
9. Dusek P., Jankovic J., Le W. Iron dysregulation in movement disorders. Neurobiol. Dis. 2012, 46:1-18.
10. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol. Aging 2009, 30:337-352.
11. Focht S.J., Snyder B.S., Beard J.L., Van Gelder W., Williams L.R., Connor J.R. Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains. Neuroscience 1997, 79:255-261.
12. Friedman A., Galazka-Friedman J., Koziorowski D. Iron as a cause of Parkinson disease - a myth or a well established hypothesis?. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S212-S214.
13. Garrido-Gil P., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2012, 9:38.
14. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Jhaveri V.V., Poczobutt A.M., Weyhenmeyer J.A., Zawada W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007, 2:1.
15. Griendling K.K., Sorescu D., Ushio-Fukai M. NADPH oxidase: role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
16. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 1991, 56:446-451.
17. Ishizaka N., Aizawa T., Yamazaki I., Usui S., Mori I., Kurokawa K., Tang S.S., Ingelfinger J.R., Ohno M., Nagai R. Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration. Lab. Invest. 2002, 82:87-96.
18. Ishizaka N., Saito K., Noiri E., Sata M., Ikeda H., Ohno A., Ando J., Mori I., Ohno M., Nagai R. Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1063-R1070.
19. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., Youdim M.B. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 1992, 59:1168-1171.
20. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
21. Kaur D., Lee D., Ragapolan S., Andersen J.K. Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic. Biol. Med. 2009, 46:593-598.
22. Labandeira-Garcia J.L., Rodriguez-Pallares J., Dominguez-Meijide A., Valenzuela R., Villar-Cheda B., Rodríguez-Perez A.I. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov. Disord. 2013, 28:1337-1342.
23. Leitner D.F., Connor J.R. Functional roles of transferrin in the brain. Biochim. Biophys. Acta 2012, 1820:393-402.
24. Li X.C., Zhuo J.L. Nuclear factor-kappaB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury. Curr. Opin. Nephrol. Hypertens. 2008, 17:37-43.
25. Li X., Jankovic J., Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J. Neural Transm. 2011, 118:473-477.
26. Lopes K.O., Sparks D.L., Streit W.J. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 2008, 56:1048-1060.
27. MacKenzie E.L., Ray P.D., Tsuji Y. Role and regulation of ferritin H in rotenone-mediated mitochondrial oxidative stress. Free Radic. Biol. Med. 2008, 44:1762-1771.
28. Mehlhase J., Sandig G., Pantopoulos K., Grune T. Oxidation-induced ferritin turnover in microglial cells: role of proteasome. Free Radic. Biol. Med. 2005, 38:276-285.
29. Mehlhase J., Gieche J., Widmer R., Grune T. Ferritin levels in microglia depend upon activation: modulation by reactive oxygen species. Biochim. Biophys. Acta 2006, 1763:854-859.
30. Mertens B., Vanderheyden P., Michotte Y., Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst. 2009, 11:49-56.
31. Orino K., Lehman L., Tsuji Y., Ayaki H., Torti S.V., Torti F.M. Ferritin and the response to oxidative stress. Biochem. J. 2001, 357(Pt 1):241-247.
32. Oro C., Qian H., Thomas W.G. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol. Ther. 2007, 113:210-226.
33. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
34. Righi M., Mori L., De Libero G., Sironi M., Biondi A., Mantovani A., Donini S.D., Ricciardi-Castagnoli P. Monokine production by microglial cell clones. Eur. J. Immunol. 1989, 19:1443-1448.
35. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
36. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system. Brain 2012, 135:124-138.
37. Rodriguez-Perez A.I., Dominguez-Meijide A., Lanciego J.L., Guerra M.J., Labandeira-Garcia J.L. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. Age (Dordr.) 2013, 35:1675-1690.
38. Saito K., Ishizaka N., Aizawa T., Sata M., Iso-o N., Noiri E., Mori I., Ohno M., Nagai R. Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1836-H1843.
39. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 2002, 91:406-413.
40. Snyder A.M., Connor J.R. Iron, the substantia nigra and related neurological disorders. Biochim. Biophys. Acta 2009, 1790:606-614.
41. Tham D.M., Martin-McNulty B., Wang Y.X., Wilson D.W., Vergona R., Sullivan M.E., Dole W., Rutledge J.C. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics 2002, 11:21-30.
42. Todorich B., Pasquini J.M., Garcia C.I., Paez P.M., Connor J.R. Oligodendrocytes and myelination: the role of iron. Glia 2009, 57:467-478.
43. Unger T., Chung O., Csikos T., Culman J., Gallinat S., Gohlke P., Höhle S., Meffert S., Stoll M., Stroth U., Zhu Y.Z. Angiotensin receptors. J. Hypertens. 1996, 14(Suppl. 5):S95-S103.
44. Urrutia P., Aguirre P., Esparza A., Tapia V., Mena N.P., Arredondo M., González-Billault C., Núñez M.T. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 2013, 126:541-549.
45. Villar-Cheda B., Sousa-Ribeiro D., Rodriguez-Pallares J., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. J. Cereb. Blood Flow Metab. 2009, 29:230-239.
46. Villar-Cheda B., Dominguez-Meijide A., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Neurobiol. Dis. 2012, 47:268-279. Role of angiotensin via angiotensin type 1 receptors.
47. Villar-Cheda B., Valenzuela R., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 2012, 33:204.e1-204.e11.
48. Weinreb O., Mandel S., Youdim M.B., Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic. Biol. Med. 2013, 62:52-64.
49. Wright J.W., Harding J.W. Importance of the brain Angiotensin system in Parkinson's disease. Park. Dis. 2012, 2012:860923.
50. Yoshida T., Tanaka M., Sotomatsu A., Hirai S. Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci. Lett. 1995, 190:21-24.
51. Zalba G., San Jose G., Moreno M.U., Fortuño M.A., Fortuño A., Beaumont F.J., Díez J. Oxidative stress in arterial hypertension. Role of NADPH oxidase. Hypertension 2001, 38:1395-1399.
52. Zecca L., Gallorini M., Schünemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 2001, 76:1766-1773.
53. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., Giaveri G., Arosio P., Santambrogio P., Fariello R.G., Karatekin E., Kleinman M.H., Turro N., Hornykiewicz O., Zucca F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9843-9848.
54. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
55. Zhang X., Surguladze N., Slagle-Webb B., Cozzi A., Connor J.R. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 2006, 54:795-804.